Clinical Trial Update: Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV [Phase 2]

View source ↗

Summary

An update on a Phase II trial of the immunotherapy AGS-004 in ART-treated HIV-infected subjects, noting the study status as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• AGS-004

Snippet

Sponsor: Argos Therapeutics | Conditions: HIV Infections | Phase 2 | Status: COMPLETED